Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.11
- Piotroski Score 3.00
- Grade Overweight
- Symbol (REPL)
- Company Replimune Group, Inc.
- Price $12.08
- Changes Percentage (0.5%)
- Change $0.06
- Day Low $11.73
- Day High $12.33
- Year High $12.86
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $17.00
- High Stock Price Target $43.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.24
- Trailing P/E Ratio -2.44
- Forward P/E Ratio -2.44
- P/E Growth -2.44
- Net Income $-215,794,000
Income Statement
Quarterly
Annual
Latest News of REPL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nvidia Joined Dow 30 After 6,000x Increase-It's Time To Replace Index
Nvidia's addition to the Dow 30 highlights the outdated nature of the index. The Entrepreneur 30 Total Return Index (ER30TR) is a more forward-looking alternative, outperforming Dow 30 significantly s...
By Forbes | 14 hours ago -
Nvidia Joins Dow Jones, Replacing Intel as Focus Shifts to AI Growth
Nvidia's share price rose 1% as it replaced Intel in the Dow Jones Industrial Average's top 30 U.S. stocks. The move reflects Nvidia's AI and technology impact, driven by its Hopper chips....
By Yahoo! Finance | 21 hours ago -
Sherwin-Williams Shares Climb as It Prepares to Join Dow, Replacing Dow Inc.
Sherwin-Williams (NYSE:SHW) will join the Dow Jones Industrial Average (DJIA) on Nov. 8, replacing Dow (DOW). This move reflects the index's aim to include diverse blue-chip leaders....
By Yahoo! Finance | 21 hours ago
